“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.
In this video, Svetlana Avulova, MD, discusses how clinicians can minimize the adverse events associated with radical cystectomy. Avulova is an assistant professor of surgery in urologic oncology at the Albany Medical Center in Albany, New York.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.